News

BETHESDA, MD – August 1, 2019 – Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale.

Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that James Keeling has been appointed as Chief Financial Officer (CFO).


James joins from JGK Financial Management, a company set up to support SMEs in their growth phase providing expertise in business & financial planning, funding, sustainable investments and exit strategies. This has included working with business based in Loughborough University Science, Enterprise Park and as Interim CFO for Stevenage Bioscience Catalyst.

The 2019 CRACK IT Challenges competition consists of three Challenges identified jointly by the NC3Rs and Sponsors.


- Challenge 32 Transgene Track: (Two Phase Challenge Sponsored by GSK and Novartis).

- Challenge 33 CleanCut: (Two Phase Challenge Sponsored by Novartis, Bayer and Takeda).

- Challenge 34 Sharp and to the Point: (Single Phase Challenge Sponsored by AstraZeneca, GSK, The University of Sheffield and The Royal Veterinary College).

center            center


Cambridge, UK: 31st July 2019


 


ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR


Life Sciences industry company operations and communications expert joins the region’s Life Science & Healthcare membership organisation


 

Westbury, NY – July 23, 2019 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today outlined several scientific contributions that it will be making at the 12th International ISSX Meeting. This conference will be held from July 28-31 at the Oregon Convention Center in Portland, OR.

The AMR Centre Ltd has today announced a landmark agreement with the Japanese pharma company Shionogi to take forward its anti-virulence program, COT-143. The therapy is designed to help the body tackle Pseudomonas aeruginosa infections, a hard to treat drug-resistant pathogen recognised by the WHO as a critical threat to human health.

AMSBIO has introduced a new range of homogeneous proximity assays, critical enzymes and small molecule inhibitors to assess the chemical adaptor function of Proteolysis Targeting Chimeras (PROTACs).

Closed Loop Medicine (CLM) announces £1.3m grant funding from Innovate UK, Longwall Capital and IQ Capital as part of today’s IUK £16m funding announcement.



CLM is an early stage UK therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised therapy regimens underpinned by digital health solutions. 

Research Triangle Park, NC, USA and Cambridge, UK, and Lyon, France,  July 18, 2019 -- Inivata, a leader in liquid biopsy, and the Centre Léon Bérard cancer center in Lyon, France, today announce the start of a randomized phase III clinical trial to evaluate time to appropriate treatment in patients with suspected metastatic lung cancer, using Inivata’s InVisionFirst®-Lung liquid biopsy test compared to standard of care tissue biopsy. This is the first interventional study for Inivata’s InVisionFirst-Lung liquid biopsy test.

Pages